



## **BRL-50481**

Catalog No: tcsc0032567

Available Sizes
Size: 5mg
Size: 10mg
Size: 25mg
Size: 50mg
Size: 100mg
Specifications
<b>CAS No:</b> 433695-36-4
Formula: $C_9^H_{12}^N_2^O_4^S$
Pathway: Metabolic Enzyme/Protease
Target: Phosphodiesterase (PDE)
Purity / Grade: >98%
Solubility: DMSO : 300 mg/mL (1228.15 mM; Need ultrasonic and warming)
Observed Molecular Weight: 244.27



## **Product Description**

BRL-50481 is a novel and selective inhibitor of **PDE7** with  $IC_{50}$ s of 0.15, 12.1, 62 and 490  $\mu$ M for **PDE7A**, **PDE7B**, **PDE4** and **PDE3**, respectively.

IC50 & Target: IC50: 0.15  $\mu$ M (PDE7A), 12  $\mu$ M (PDE7B), 62  $\mu$ M (PDE4), 490  $\mu$ M (PDE3)  $^{[1]}$ 

In Vitro: BRL-50481 increases the cAMP content (19.1 $\pm$ 6.2% of IBMX response at 300 μM) but is considerably less potent. BRL-50481 (30 μM) fails to suppress proliferation by itself but significantly potentiates the effect of rolipram. BRL-50481 (30 μM) has no effect on IL-15-induced proliferation but augments the inhibitory effect of rolipram. Pretreatment (30 min) of human monocytes with BRL-50481 has, by itself, a negligible ( $\sim$ 2 to 10%) inhibitory effect on TNFα output at all concentrations tested. BRL-50481 also potentiates the inhibitory effect of PGE<sub>2</sub> on LPS-induced TNFα release. BRL-50481 has no significant effect by itself on κB-dependent transcription (5.6 $\pm$ 1.9% inhibition at 30 μM) and fails to enhance the effect of rolipram (maximum inhibition, 52.9 $\pm$ 2.7%; pIC<sub>30</sub> value of 5.33 $\pm$ 0.12). BRL-50481 suppresses, in a concentration-dependent manner, LPS-induced TNFα release in monocytes in which PDE7A1 is induced (21.7 $\pm$ 1.6% inhibition at 30 μM at the 12-h time point)<sup>[2]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!